Intas Pharmaceuticals’ new warning letter from the U.S. FDA reads like a checklist of what not to do when the regulator pays a visit to your manufacturing facility. The FDA handed Intas a ...

Following a pair of similar deals in January and June, Coherus BioSciences has netted itself a hefty chunk of change for the last biosimilar in its portfolio, in turn freeing up the company to go ...

SINGAPORE--(BUSINESS WIRE)--Prestige Biopharma Limited (KRX: 950210, hereafter referred to as “Prestige”) and Intas Pharmaceuticals Limited (hereafter referred to as “Intas”) today announced that the ...

Asked how large is the Indian pharma industry, Intas Pharmaceuticals' Global Operations CEO Rakesh Bamzai said at NDTV World Summit: "Around 50-55 billion dollars. And 20-25 billion dollars worth ...